Integer (ITGR) investor relations material

Strategic review and business continuity

• A strategic review process was initiated due to heightened interest, aiming to maximize shareholder value, with the process expected to last months rather than years.

• The board is considering all options, including remaining public or pursuing alternatives, driven by recent increased interest.

• Communication with employees and customers has emphasized business continuity and value delivery, with no reported concerns or disruptions.

• No structural changes are anticipated regardless of the outcome, and operations remain business as usual.

Guidance changes and market dynamics

• Two guidance revisions occurred: one in late 2025 due to lower-than-expected adoption of three products, and another in early 2026 related to inventory adjustments in the electrophysiology (EP) segment.

• Rapid adoption of PFA technology in EP led to unpredictable market dynamics and inventory fluctuations.

• No structural business changes were identified; most revenue remains visible through rolling forecasts and a stable backlog.

• Return to market growth is now expected in Q4 2026, with above-market growth targeted for 2027, both delayed by one quarter.

• Additional risk adjustments have been incorporated into guidance to account for unforeseen events.

Portfolio exposure and growth outlook

• The business remains diversified, with no single product accounting for more than 2-3% of revenue.

• Exposure exists across multiple MedTech markets, including EP, neuromodulation, and renal denervation, though the latter is not expected to be a significant near-term driver.

• Growth from three previously high-performing products is not expected to resume, but stabilization is anticipated.

• New product launches in late 2026 and 2027 are expected to drive a return to 200 basis points above market growth in 2027.